Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Methylphenidate ERCT in 4-5 Year Olds
NCT03546400Phase 4Withdrawn
- Sponsor
- Pfizer
- Start
- Sep 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of methylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by Pfizer. Primary endpoints: Time to Maximum Plasma Concentration at 2 weeks, Maximum Plasma Concentration at 2 weeks and 8 more. Planned start Sep 2018; status: withdrawn.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03546400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03546400.